Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil
Mem. Inst. Oswaldo Cruz
;
99(8): 877-882, dez. 2004. ilus, graf
Artigo
em Inglês
| LILACS
| ID: lil-393772
ABSTRACT
In the context of universal access to antiretroviral therapy, the surveillance of human immunodeficiency virus type 1 (HIV-1) genetic diversity and resistance becomes pivotal. In this work our purpose was to describe the genetic variability; prevalence of drug-resistance mutations; and genotypic resistance profiles in HIV-1 infected individuals under antiretroviral treatment, from the Federal District, Brasília, Central Brazil. The entire viral protease and codons 19 to 234 of the reverse transcriptase gene from 45 HIV-1 isolates were amplified and sequenced for subtyping and genotyping. By phylogenetic analysis, 96 percent of the samples clustered with subtype B and the remaining 4 percent with HIV-1 subtype F sequences. One major protease inhibitor resistance-associated mutation, I50V, was detected in 38 percent of the samples. Minor mutations were also found at the protease gene L10I/V (7 percent), K20M (2 percent), M36I (11 percent), L63P (20 percent), A71T (2 percent), and V77I (7 percent). Many mutations associated with reduced susceptibility to nucleoside or non-nucleoside reverse transcriptase inhibitors were detected M41L (11 percent), E44D (4 percent), D67N (11 percent), T69D (2 percent), K70R (11 percent), L74V (2 percent), L100I (4 percent), K103N (18 percent), V118I (9 percent), Y181C (11 percent), M184V (18 percent), G190A (4 percent), T215Y (4 percent), and K219E (4 percent). This study has shown that 84 percent of the studied population from the Federal District, showing evidences of therapy failure, presented viral genomic mutations associated with drug resistance. The main antiretrovirals to which this population showed resistance were the PI amprenavir (38 percent), the NNRTIs delavirdine, nevirapine (31 percent), and efavirenz (24 percent), and the NRTIs lamivudine (18 percent), abacavir, and zidovudine (13 percent).
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Infecções por HIV
/
HIV-1
/
Fármacos Anti-HIV
/
Farmacorresistência Viral
Tipo de estudo:
Fatores de risco
Limite:
Humanos
País/Região como assunto:
América do Sul
/
Brasil
Idioma:
Inglês
Revista:
Mem. Inst. Oswaldo Cruz
Assunto da revista:
Medicina Tropical
/
Parasitologia
Ano de publicação:
2004
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Agência Nacional de Vigilância Sanitária/BR
/
Laboratório Central de Saúde Pública do Distrito Federal/BR
/
Universidade de Brasília/BR
Similares
MEDLINE
...
LILACS
LIS